CBG(000009)2024-07-10 10:53Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 198 million and 250 million yuan, representing a decline of 49.15% to 59.73% compared to the same period last year[2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 201 million and 253 million yuan, a decrease of 23.26% to 39.03% year-on-year[2]. - The basic earnings per share are projected to be between 0.0768 yuan and 0.0969 yuan, down from 0.1906 yuan per share in the previous year[2]. Reasons for Decline - The decline in net profit is primarily due to cost-cutting pressures in downstream markets and intensified competition leading to lower product prices[3]. - The company's high-tech subsidiaries have experienced a significant year-on-year decline in net profit[3]. - The fair value of financial assets held by the company, such as Fangyuan shares, has decreased year-on-year due to secondary market fluctuations[3]. - The previous year's profit included significant gains from the disposal of Dafu Pharmaceutical shares, which are not present in the current reporting period[3]. Non-Recurring Gains and Losses - Non-recurring gains and losses mainly consist of government subsidies, gains from trading financial assets, and reversals of impairment provisions for receivables[3]. Financial Reporting - The financial data in this earnings forecast has not been audited by the accounting firm[3]. - The specific financial data will be disclosed in the company's 2024 semi-annual report[4].